NCT06449313View on ClinicalTrials.gov

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

September 30, 2032

Conditions
Non-small Cell Lung Cancer Stage III
Interventions
DRUG

Cemiplimab-Rwlc

350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.

Trial Locations (1)

20007

RECRUITING

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Georgetown University

OTHER